SAN DIEGO, June 18, 2015 /PRNewswire/ -- Sequenom, Inc.
(NASDAQ: SQNM), a life sciences company committed to enabling
healthier lives through the development of innovative products and
services, today announced that its shareholders elected
Catherine J. Mackey, Ph.D., as a new
member of its Board of Directors, effective June 17, 2015. Dr. Mackey has also been appointed
to the Audit and Nominating and Corporate Governance committees of
the Company's Board of Directors.
"We are pleased to welcome Dr. Mackey to our board, and we look
forward to drawing on her more than 30 years of executive
leadership and strong expertise in research and development as we
expand our testing portfolio and drive continued growth for the
company," said Kenneth F. Buechler,
Ph.D., Chairman of Sequenom, Inc.'s Board of Directors.
Dr. Mackey is currently the Chief Executive Officer of CYPrus
Therapeutics, Inc., a privately-held small molecule pharmaceutical
development company. She is a Special Advisor to Fortis Advisors
LLC, and serves on the Scientific Advisory Boards of FHOOSH, Inc.
and Cypher Genomics. In addition, Dr. Mackey is a director and a
member of the Finance and Audit & Compliance Committees of Rady
Children's Hospital and is past-chair of CONNECT. Dr. Mackey
currently serves on the boards of privately-held companies Cour
Pharmaceutical Development Company (Chair), Evolve Biosystems, Inc.
and Viventia Bio, Inc.
Prior to her current roles, Dr. Mackey served as the Senior Vice
President of Worldwide Research and Development at Pfizer Inc. from
2001 through 2010 and is credited with leading Pfizer's La Jolla
Labs to become one of Pfizer's most successful R&D sites.
Before that, Dr. Mackey was Vice President of Strategic Alliances
at Pfizer's R&D headquarters in Connecticut and the Leader of Genomic and
Proteomic Sciences at Pfizer. Leading up to her time at Pfizer, Dr.
Mackey held positions of increasing responsibility for DEKALB
Genetics including Vice President and Head of Research and
Development.
Dr. Mackey received her B.S. and Ph.D. degrees in microbiology
from Cornell University.
About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is
committed to enabling healthier lives through the development of
innovative products and services. The Company serves patients
and physicians by providing early patient management information.
To learn how Sequenom is interpreting the genome to improve
your life, visit www.sequenom.com.
Forward-Looking Statements
Statements contained in
this press release regarding matters that are not historical facts
are "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
regarding the development of innovative products and services,
expanding our testing portfolio and driving continued growth for
the company. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements.
Risks are described more fully in the Company's filings
with the Securities and Exchange Commission, including without
limitation the Company's most recent Quarterly Report on Form 10-Q
and other documents subsequently filed with or furnished to the
Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. The Company undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
Logo - http://photos.prnewswire.com/prnh/20040415/SQNMLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sequenom-welcomes-catherine-j-mackey-phd-to-board-of-directors-300101107.html
SOURCE Sequenom, Inc.